Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 12:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 19,396 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Efficacy and Safety Clear all
Recruiting Phase 3 Interventional

Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer

NCT07480356
View directory record Official record
Conditions
Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Interventions
TARA-002, Investigator's Choice of Intravesical Chemotherapy
Drug
Lead sponsor
Protara Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
9
States / cities
Queen Creek, Arizona • Little Rock, Arkansas • Bakersfield, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 8, 2026, 12:23 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

NCT01090310
View directory record Official record
Conditions
Non-infectious Uveitis
Interventions
AIN457, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
10
States / cities
Beverly Hills, California • Atlanta, Georgia • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 8, 2026, 12:23 AM EDT
Completed Phase 3 Interventional Results available

Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B

NCT02234310
View directory record Official record
Conditions
Hemophilia B
Interventions
rFIXFc
Biological
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
Up to 17 Years · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
11
States / cities
Sacramento, California • Washington D.C., District of Columbia • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 8, 2026, 12:23 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849

NCT05761223
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
Phase Ia dose-escalation part of FB849 Monotherapy, Phase Ib dose-expansion of FB849 monotherapy, Phase IIb dose-escalation part of FB849 in Combination with Pembrolizumab, Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type A cancer), Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type B cancer), Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type C cancer)
Drug
Lead sponsor
1ST Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Cleveland, Ohio • Dallas, Texas • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 8, 2026, 12:23 AM EDT
Completed Phase 2 Interventional Results available

CT-011 MAb in DLBCL Patients Following ASCT

NCT00532259
View directory record Official record
Conditions
Lymphoma, Large Cell, Diffuse, Lymphoma, Mixed Cell, Diffuse, Primary Mediastinal Large B-Cell Lymphoma
Interventions
CT-011
Drug
Lead sponsor
CureTech Ltd
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
20
States / cities
La Jolla, California • San Diego, California • Atlanta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2014 · Synced Oct 8, 2026, 12:23 AM EDT
Completed Phase 3 Interventional

Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects

NCT04629703
View directory record Official record
Conditions
Covid19, SARS (Severe Acute Respiratory Syndrome), SARS Pneumonia, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Pneumonia, Pneumonia, Viral
Interventions
Fostamatinib, Placebo
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Orange, California • Washington D.C., District of Columbia • Hialeah, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 8, 2026, 12:23 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors

NCT01689727
View directory record Official record
Conditions
Pituitary Tumors
Interventions
Technetium Tc 99m EC20
Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 8, 2026, 12:23 AM EDT
Completed Not applicable Interventional

A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer

NCT03719742
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Sponsor Test Products
Other
Lead sponsor
Burt's Bees Inc.
Industry
Eligibility
6 Months to 7 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2019 · Synced Oct 8, 2026, 12:23 AM EDT
Active, not recruiting Not applicable Interventional

Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®

NCT01644669
View directory record Official record
Conditions
Invasive Ductal Carcinoma, Ductal Carcinoma in Situ
Interventions
Intra-operative Radiation Therapy - IORT
Radiation
Lead sponsor
Xoft, Inc.
Industry
Eligibility
40 Years and older · Female only
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2029
U.S. locations
22
States / cities
Tucson, Arizona • Duarte, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 8, 2026, 12:23 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)

NCT03363841
View directory record Official record
Conditions
Candidiasis, Invasive, Candidemia
Interventions
SCY-078
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Jersey City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 8, 2026, 12:23 AM EDT
Terminated Phase 3 Interventional Results available

PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780541
View directory record Official record
Conditions
COVID-19
Interventions
PF-07304814, Placebo, Remdesivir
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
31
States / cities
Chula Vista, California • Los Angeles, California • Mather, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 8, 2026, 12:23 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)

NCT05668741
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-522 mRNA therapy, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
Birmingham, Alabama • Long Beach, California • Palo Alto, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 8, 2026, 12:23 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)

NCT03068754
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Acthar, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 75 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
39
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 8, 2026, 12:23 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)

NCT02870205
View directory record Official record
Conditions
Seasonal Allergic Rhinitis (SAR)
Interventions
GSP 301 NS, GOM-NS, GMM-2 NS, GSP 301 placebo NS
Drug
Lead sponsor
Glenmark Specialty S.A.
Industry
Eligibility
12 Years and older
Enrollment
1,176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
43
States / cities
Mission Viejo, California • Orange, California • San Diego, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 8, 2026, 12:23 AM EDT
Suspended Not applicable Interventional

The Selective Cytopheretic Device (SCD) for Acute Kidney Injury (AKI) and Hepatorenal Syndrome (HRS) Type I

NCT04898010
View directory record Official record
Conditions
Acute Kidney Injury, Hepatorenal Syndrome
Interventions
Selective Cytopheretic Device
Device
Lead sponsor
Lenar Yessayan
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 8, 2026, 12:23 AM EDT
Terminated Phase 1 Interventional

Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

NCT04795713
View directory record Official record
Conditions
Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
Interventions
MT-6402
Drug
Lead sponsor
Molecular Templates, Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • Newnan, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 8, 2026, 12:23 AM EDT
Not listed Phase 4 Interventional

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

NCT00131313
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Nipent, Cytoxan, Rituxan
Drug
Lead sponsor
East Valley Hematology and Oncology Medical Group
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
52
States / cities
Muscle Shoals, Alabama • Burbank, California • Concord, California + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2005 · Synced Oct 8, 2026, 12:23 AM EDT
Completed Not applicable Interventional Results available

PillSense System for Detecting UGI Bleed

NCT05385224
View directory record Official record
Conditions
UGI Bleed, Upper Gastrointestinal Bleeding, Upper Gastrointestinal Bleed
Interventions
PillSense
Diagnostic Test
Lead sponsor
EnteraSense Limited
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 8, 2026, 12:23 AM EDT
Completed Phase 1Phase 2 Interventional

Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer

NCT00043823
View directory record Official record
Conditions
Lung Cancer
Interventions
Avastin, Tarceva
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 8, 2026, 12:23 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer

NCT01812746
View directory record Official record
Conditions
CRPC, Prostate Cancer
Interventions
BIND-014
Drug
Lead sponsor
BIND Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Fort Meyers, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2016 · Synced Oct 8, 2026, 12:23 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of ABT-436 in Major Depressive Disorder

NCT01741142
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ABT-436, Escitalopram, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
18
States / cities
Little Rock, Arkansas • Garden Grove, California • National City, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2013 · Synced Oct 8, 2026, 12:23 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma

NCT05525286
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
SOT102
Drug
Lead sponsor
SOTIO Biotech a.s.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
St Louis, Missouri • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 8, 2026, 12:23 AM EDT
Completed Not applicable Interventional

Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris

NCT03303170
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Sebacia Microparticles, Nd:Yag Laser
Device
Lead sponsor
Sebacia, Inc.
Industry
Eligibility
12 Years to 45 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Scottsdale, Arizona • San Diego, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Oct 8, 2026, 12:23 AM EDT
Completed Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough Pain

NCT00214955
View directory record Official record
Conditions
Chronic Neuropathic Pain
Interventions
ORAVESCENT Fentanyl Citrate
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
17
States / cities
Jonesboro, Arkansas • Bakersfield, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 8, 2026, 12:23 AM EDT